Effect of Supplemental Oxygen Therapy on Neurocognitive Performance in Healthy Highlanders
ConditionNeurocognition
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Zurich
About this trial
Exposure to high altitudes, defined as locations above 2500 m, has been shown to cause cognitive alternations due to reduced blood oxygenation (SpO2). However, it remains to be determined whether cognitive changes are present in highlanders living at moderate altitudes (2500 m) and whether cognitive alterations are reversible with supplemental oxygen therapy (SOT).
Eligibility criteria
Qualifiers
Signed written consent
Age >18
Kyrgyz ethnicity
Born, raised and living at approximately 2500 m
Disqualifiers
Severe disease such as unstable hypertension, coronary heart disease, pulmonary diseases, others.
Regular use of medication that interfere with sleep or breathing such as benzodiazepines, opioids, acetazolamide
Heavy smoking of >20 cigarettes per day
Not able to read or adhere to the study protocol
Trial design
Treatments tested in this trial
- Supplemental oxygen therapy
- Sham intervention
Treatment groups
50 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
University of Zurich
Lead sponsor
National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov
Collaborator
Source ClinicalTrials.gov